Cargando…

How to reduce bacillus Calmette-Guérin discontinuation in patients with severe functional impairment

BACKGROUND: Severe functional impairment is often considered a contraindication to intravesical therapy for nonmuscle-invasive bladder cancer (NMIBC). A tailored intravesical bacillus Calmette-Guérin (BCG) procedure was evaluated in high-risk (HR)-NMIBC patients with severe functional impairment. MA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Gianfrancesco, Luca, Ragonese, Mauro, Foti, Massimiliano, Palermo, Giuseppe, Sacco, Emilio, Bassi, PierFrancesco, Racioppi, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Special Topic: Advances in bladder cancer therapy: Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527929/ https://www.ncbi.nlm.nih.gov/pubmed/36204364 http://dx.doi.org/10.1097/CU9.0000000000000134

Ejemplares similares

The indispensable role of urinalysis for patients undergoing treatment for nonmuscle invasive bladder cancer
por: Di Gianfrancesco, Luca, et al.
Publicado: (2022)

Patient Preferences for Treatment of Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: A Cross-country Choice Experiment
por: Collacott, Hannah, et al.
Publicado: (2023)

Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
por: Tan, Wei Shen, et al.
Publicado: (2023)

A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
por: Kulkarni, Girish S., et al.
Publicado: (2022)

Partial Versus Complete Bacillus Calmette-Guérin Intravesical Therapy and Bladder Cancer Outcomes in High-risk Non–muscle-invasive Bladder Cancer: Is NIMBUS the Full Story?
por: Rezaee, Michael E., et al.
Publicado: (2021)

Quality of Life in Patients with High-grade Non–muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial
por: van Straten, Christine G.J.I., et al.
Publicado: (2023)

The Use of Urine Mycobacterium tuberculosis Complex Polymerase Chain Reaction as a Predictive Factor for Recurrence and Progression After Intravesical Bacillus Calmette-Guérin Therapy in Patients with Non–muscle‑invasive Bladder Cancer
por: Muto, Satoru, et al.
Publicado: (2021)

Treatment and disease management patterns for bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia: A real-world data analysis
por: Broughton, Edward I., et al.
Publicado: (2022)

The association between postvoid residual and response to standard therapy in male and female patients with non–muscle-invasive bladder cancer
por: Di Gianfrancesco, Luca
Publicado: (2023)

ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes
por: Racioppi, Marco, et al.
Publicado: (2018)

Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?
por: Racioppi, Marco, et al.
Publicado: (2019)

Improved Non-Invasive Diagnosis of Bladder Cancer with an Electronic Nose: A Large Pilot Study
por: Bassi, PierFrancesco, et al.
Publicado: (2021)

A retrospective analysis of the factors associated with increased risk of readmission within 30 days after primary transurethral resection of bladder tumor
por: Jindal, Tarun, et al.
Publicado: (2023)

Depth of invasion to the bladder wall as a prognostic factor and its association with circulating cell-free DNA levels in patients with muscle-invasive bladder cancer
por: Iemura, Yusuke, et al.
Publicado: (2023)

Can magnetic resonance imaging differentiate muscle invasion (T2) and lamina propria invasion (T1) urothelial carcinoma of the bladder? A systematic review and meta-analysis of Vesical Imaging-Reporting and Data System accuracy
por: Jazayeri, Seyed Behzad, et al.
Publicado: (2023)

A radiation-related second primary gastrointestinal stromal tumor in the bladder
por: Hori, Mai, et al.
Publicado: (2023)

Construction and evaluation of a novel prognostic risk model of aging-related genes in bladder cancer
por: Wang, Delin, et al.
Publicado: (2023)

Predictors of time-to-nadir serum creatinine after drainage of bilaterally obstructed kidneys due to bladder cancer
por: Gadelkareem, Rabea Ahmed, et al.
Publicado: (2023)

Patient-derived bladder cancer organoid model to predict sensitivity and feasibility of tailored precision therapy
por: Jiang, Ying, et al.
Publicado: (2023)

The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer
por: Cahill, Ellen M., et al.
Publicado: (2022)

The era of personalized treatments: Updates on immunotherapy within urothelial of bladder cancer
por: Wu, Zhang-Song, et al.
Publicado: (2022)

Bacillus Calmette–Guérin Immunotherapy for Cancer
por: Cardillo, Fabíola, et al.
Publicado: (2021)

Validation and Reliability Testing of the EORTC QLQ-NMIBC24 Questionnaire Module to Assess Patient-reported Outcomes in Non–Muscle-invasive Bladder Cancer
por: Blazeby, Jane M., et al.
Publicado: (2014)

The Significant Role of Depression in Elderly Patients with Bladder Cancer
por: Oserowsky, Alexander, et al.
Publicado: (2021)

Defining Factors Associated with High-quality Surgery Following Radical Cystectomy: Analysis of the British Association of Urological Surgeons Cystectomy Audit
por: Tan, Wei Shen, et al.
Publicado: (2021)

Trial-based Cost-effectiveness Analysis of an Immediate Postoperative Mitomycin C Instillation in Patients with Non–muscle-invasive Bladder Cancer
por: Hentschel, Anouk E., et al.
Publicado: (2022)

SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer
por: Lindgren, Maria Skydt, et al.
Publicado: (2021)

Learning Curve Analysis for Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section Scientific Working Group
por: Wijburg, Carl J., et al.
Publicado: (2022)

A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice
por: de Ruiter, Ben-Max, et al.
Publicado: (2022)

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)

Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans
por: Kumar, Abhishek, et al.
Publicado: (2021)

Intensified and Standardized Digital Communication with Cystectomy Patients as a Potentially Simple and Effective Modality for Early Detection of Postoperative Complications: Results from a Pilot Study
por: Birkhäuser, Frédéric D., et al.
Publicado: (2020)

Impact of Diagnosing Urologists and Hospitals on the Use of Radical Cystectomy
por: Golla, Vishnukamal, et al.
Publicado: (2020)

Living with Bladder Cancer: Self-reported Changes in Patients’ Functional and Overall Health Status Following Diagnosis
por: Ungerer, Garrett, et al.
Publicado: (2020)

Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer
por: Maibom, Sophia L., et al.
Publicado: (2021)

Development of the First Patient-centred Set of Outcomes for Muscle-invasive and Metastatic Bladder Cancer: A Multicentre Initiative
por: Reesink, Daan J., et al.
Publicado: (2021)

Sexual Dimorphism in Outcomes of Non–muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint
por: Chenard, Stephen, et al.
Publicado: (2021)

Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer
por: Schmidt, Bogdana, et al.
Publicado: (2022)

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
por: Besançon, Marjorie, et al.
Publicado: (2022)

Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis
por: Ghali, Fady, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0tashdihle5784f18kkk4kq310